HC Wainwright Lowers Earnings Estimates for Shattuck Labs

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Shattuck Labs in a report released on Thursday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.55) per share for the year, down from their prior forecast of ($0.42). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.70) EPS.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03).

A number of other brokerages have also recently weighed in on STTK. Wedbush raised their price objective on Shattuck Labs from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, October 2nd. UBS Group assumed coverage on Shattuck Labs in a research note on Sunday, October 11th. They issued a “buy” rating and a $17.00 target price for the company. Needham & Company LLC upped their target price on Shattuck Labs from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Leerink Partners began coverage on shares of Shattuck Labs in a research report on Monday, July 20th. They set an “outperform” rating and a $16.00 price target on the stock. Finally, TD Cowen raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $13.70.

Shattuck Labs Trading Down 2.8%

STTK opened at $4.85 on Monday. The stock has a 50-day moving average price of $5.92 and a 200-day moving average price of $6.03. Shattuck Labs has a 12-month low of $1.72 and a 12-month high of $8.33. The stock has a market capitalization of $493.92 million, a P/E ratio of -9.51 and a beta of 1.21.

Institutional Trading of Shattuck Labs

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Shattuck Labs during the second quarter valued at about $27,315,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Shattuck Labs in the 2nd quarter valued at about $26,025,000. Wellington Management Group LLP bought a new stake in shares of Shattuck Labs in the 2nd quarter valued at about $12,269,000. S&G Foundation bought a new stake in shares of Shattuck Labs in the 2nd quarter valued at about $3,024,000. Finally, Deutsche Bank AG purchased a new stake in Shattuck Labs during the 2nd quarter valued at about $2,474,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule. Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.